European Society for Medical Oncology Congress

Temporary ovarian suppression during chemotherapy may reduce the risk for infertility in young women with breast cancer, according to results of a meta-analysis presented at the European Cancer Congress.

Nintedanib, a triple angiokinase inhibitor, was found to be safe for treating patients with hepatocellular carcinoma and mild or moderate liver impairment, according to data from a phase 1 trial presented at the European Society for Medical Oncology’s European Cancer Congress.

A combination of targeted agents dabrafenib and trametinib significantly improved survival in patients with BRAF V600-mutated advanced melanoma compared with vemurafenib monotherapy, according to study findings presented at the European Society of Medical Oncology’s European Cancer Congress.

Everolimus conferred a statistically significant and clinically meaningful PFS benefit with an acceptable safety profile in patients with advanced, progressive neuroendocrine tumors of the lung or gastrointestinal region, according to phase 3 trial results presented at European Society of Medical Oncology’s European Cancer Congress.

Twice as many patients with gastrointestinal cancers who took daily aspirin post-diagnosis  survived compared with nonusers, according to findings from a large study conducted in The Netherlands and presented at the European Society of Medical Oncology’s European Cancer Congress.

In a cohort of Chinese patients, researchers found that routine blood and urine test results may be useful for predicting the probabilities of the risk for hepatocellular carcinoma, according to a poster presentation at the European Society for Medical Oncology’s European Cancer Congress.

Biopsies of primary tumors routinely failed to capture clinically significant genetic alterations in brain metastases, potentially missing actionable mutations, according to study results presented at European Society of Medical Oncology’s European Cancer Congress.

The FDA granted priority review to eribulin mesylate for patients with inoperable leiomyosarcoma and liposarcoma who have previously received chemotherapy for advanced or metastatic disease, according to a press release from the drug’s manufacturer.

Tumors in younger colorectal cancer patients may have molecular differences related to epigenetics compared to the tumors of older colorectal cancer patients, according to research presented at European Society of Medical Oncology’s European Cancer Congress.

Treatment with the peptide receptor radionuclide therapy 177-Lu-Dotatate conferred clinically meaningful and statistically significant PFS improvements among patients with advanced gastrointestinal neuroendocrine tumors, according to the results of a phase 3 study presented at European Society for Medical Oncology’s European Cancer Congress.